Biocryst Pharmaceuticals (BCRX) Change in Acquisitions & Divestments (2010 - 2026)

Biocryst Pharmaceuticals (BCRX) has 17 years of Change in Acquisitions & Divestments data on file, last reported at $221.2 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments rose 191.1% year-over-year to $221.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $401.9 million (up 43.8% YoY) and the FY2025 annual result came in at $256.6 million, down 19.92% from the prior year.
• Change in Acquisitions & Divestments advanced to $221.2 million in Q1 2026, from $49.0 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $221.2 million in Q1 2026 to a low of $4.0 million in Q2 2022.
• A 5-year average of $81.3 million and a median of $69.7 million in 2023 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2023 — Change in Acquisitions & Divestments surged 1558.12% — and 2024, when it plunged 76.03%.
• Tracing BCRX's Change in Acquisitions & Divestments over 5 years: stood at $77.7 million in 2022, then surged by 66.02% to $129.1 million in 2023, then tumbled by 55.06% to $58.0 million in 2024, then retreated by 15.52% to $49.0 million in 2025, then soared by 351.5% to $221.2 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $221.2 million (Q1 2026), $49.0 million (Q4 2025), and $73.0 million (Q3 2025), per Business Quant data.